Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...
Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... implying 31% revenue growth and nearly 80% non-GAAP EPS growth, the stock trades at an attractive level following the recent price correction ...
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...